Candel Therapeutics (NASDAQ:CADL) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $3.96 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62. The company has a market capitalization of $126.88 million, a PE ratio of -2.29 and a beta of -0.88. Candel Therapeutics has a one year low of $0.77 and a one year high of $14.30. The business has a 50 day simple moving average of $6.01 and a 200 day simple moving average of $6.73.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now owns 929,873 shares in the company, valued at approximately $5,597,835.46. The trade was a 1.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 31,800 shares of company stock worth $193,380. 41.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $31,000. FMR LLC acquired a new stake in shares of Candel Therapeutics in the 3rd quarter valued at $46,000. MetLife Investment Management LLC acquired a new stake in shares of Candel Therapeutics in the 3rd quarter valued at $87,000. Atom Investors LP acquired a new stake in shares of Candel Therapeutics in the 3rd quarter valued at $103,000. Finally, Rhumbline Advisers acquired a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $143,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.